Atea Pharmaceuticals, Inc.
AVIR
$3.10
$0.010.16%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 32.83% | 1.28% | -10.09% | -32.59% | -36.19% |
| Gross Profit | -32.83% | -1.28% | 10.09% | 32.59% | 36.19% |
| SG&A Expenses | -16.84% | -11.65% | -6.98% | -2.14% | -7.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.57% | -10.74% | -11.08% | 31.77% | 28.63% |
| Operating Income | 2.57% | 10.74% | 11.08% | -31.77% | -28.63% |
| Income Before Tax | 15.47% | 22.68% | 14.77% | -24.10% | -32.60% |
| Income Tax Expenses | -20.78% | -17.53% | -14.73% | -9.14% | 32.45% |
| Earnings from Continuing Operations | 15.51% | 22.65% | 14.77% | -23.85% | -32.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.51% | 22.65% | 14.77% | -23.85% | -32.60% |
| EBIT | 2.57% | 10.74% | 11.08% | -31.77% | -28.63% |
| EBITDA | 2.58% | 10.77% | 11.11% | -31.87% | -28.72% |
| EPS Basic | 14.34% | 23.25% | 15.73% | -22.67% | -31.63% |
| Normalized Basic EPS | -4.78% | 8.00% | 9.87% | -43.26% | -34.75% |
| EPS Diluted | 14.34% | 23.25% | 15.73% | -22.67% | -31.63% |
| Normalized Diluted EPS | -4.78% | 8.00% | 9.87% | -43.26% | -34.75% |
| Average Basic Shares Outstanding | -1.07% | 0.83% | 1.24% | 1.05% | 0.78% |
| Average Diluted Shares Outstanding | -1.07% | 0.83% | 1.24% | 1.05% | 0.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |